Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine
Open Access
- 1 August 1999
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (8), 1475-1481
- https://doi.org/10.1038/sj.gt.3300961
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Comparison of four strategies for tumour vaccination in the B16-F10 melanoma modelGene Therapy, 1998
- A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, MarylandHuman Gene Therapy, 1998
- Interleukin-2 Gene-Modified Allogeneic Tumor Cells for Treatment of Relapsed NeuroblastomaHuman Gene Therapy, 1998
- Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic VaccineHuman Gene Therapy, 1998
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Immunization with interleukin‐2‐secreting allogeneic mouse fibroblasts expressing melanoma‐associated antigens prolongs the survival of mice with melanomaInternational Journal of Cancer, 1993
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigensCancer Immunology, Immunotherapy, 1991
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivoNature, 1984